Enanta Pharmaceuticals, Inc. ENTA · Stock Open Enanta Pharmaceuticals, Inc. in new tab
Enanta Pharmaceuticals, Inc. Analysis (ENTA)
Is Enanta Pharmaceuticals, Inc. a good investment? Enanta Pharmaceuticals, Inc. (ENTA) is currently trading at 12.11 USD. Market analysts have a consensus price target of 21.83 USD. This suggests a potential upside from current levels.
Earnings Schedule: Enanta Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -2.37.
Investor FAQ
Does Enanta Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Enanta Pharmaceuticals, Inc.?
Enanta Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -2.42.
Company Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Community Discussion